Table 1 Enriched KEGG pathways of MG risk genes.
Pathway term | FDR | Pathway map |
|---|---|---|
hsa05219: Bladder cancer | 9.17E−16 | Human disease (cancers: specific types) |
hsa05161: Hepatitis B | 3.66E−15 | Human disease (Infectious disease: viral) |
hsa01522: Endocrine resistance | 3.86E−15 | Human disease (Drug resistance: antineoplastic) |
hsa01521: EGFR tyrosine kinase inhibitor resistance | 1.00E−14 | Human disease (Drug resistance: antineoplastic) |
hsa04010: MAPK signaling pathway | 4.95E−13 | Environmental Information Processing (Signal transduction) |
hsa05205: Proteoglycans in cancer | 1.28E−12 | Human diseases (Cancer: overview) |
hsa05163: Human cytomegalovirus infection | 4.01E−12 | Human disease (Infectious disease: viral) |
hsa04933: AGE-RAGE signaling pathway in diabetic complications | 4.37E−12 | Human disease (Endocrine and metabolic disease) |
hsa05220: Chronic myeloid leukemia | 8.94E−12 | Human disease (cancers: specific types) |
hsa05160: Hepatitis C | 1.94E−11 | Human disease (Infectious disease: viral) |
hsa05210: Colorectal cancer | 2.64E−11 | Human disease (cancers: specific types) |
hsa05218: Melanoma | 1.86E−10 | Human disease (cancers: specific types) |
hsa05224: Breast cancer | 1.97E−10 | Human disease (cancers: specific types) |
hsa05214: Glioma | 2.33E−10 | Human disease (cancers: specific types) |
hsa05225: Hepatocellular carcinoma | 7.35E−10 | Human disease (cancers: specific types) |
hsa05213: Endometrial cancer | 9.72E−10 | Human disease (cancers: specific types) |
hsa05216: Thyroid cancer | 1.50E−09 | Human disease (cancers: specific types) |
hsa05167: Kaposi sarcoma-associated herpesvirus infection | 2.75E−09 | Human disease (Infectious disease: viral) |
